Table 1.
Patient and sample characteristics according to the histological growth pattern present in the liver metastasi(e)s.
| Pure R-HGP | Any D-HGP | p (Fisher) | ||
|---|---|---|---|---|
| Menopausal status at primary diagnosis | Pre | 6 (40.0) | 13 (76.5) | 0.070 |
| Post | 9 (60.0) | 4 (23.5) | ||
| Missing | 1 | 3 | ||
| Age at primary diagnosis | ≤50 | 6 (37.5) | 12 (60.0) | 0.315 |
| >50 | 10 (62.5) | 8 (40.0) | ||
| TNM_T | 0 | 0 (0.0) | 1 (6.2) | 0.172 |
| 1 | 6 (46.2) | 10 (62.5) | ||
| 2 | 6 (46.2) | 3 (18.8) | ||
| 3 | 0 (0.0) | 2 (12.5) | ||
| 4 | 1 (7.7) | 0 (0.0) | ||
| Missing | 3 | 4 | ||
| TNM_N | 0 | 3 (21.4) | 10 (55.6) | 0.020 |
| 1 | 8 (57.1) | 2 (11.1) | ||
| 2 | 3 (21.4) | 6 (33.3) | ||
| Missing | 2 | 2 | ||
| TNM_M | 0 | 9 (56.2) | 14 (70.0) | 0.493 |
| 1 | 7 (43.8) | 6 (30.0) | ||
| Grade (primary) | 1 | 5 (35.7) | 2 (12.5) | 0.356 |
| 2 | 5 (35.7) | 9 (56.2) | ||
| 3 | 4 (28.6) | 5 (31.2) | ||
| Missing | 2 | 4 | ||
| ER status (primary) | Negative | 3 (21.4) | 2 (12.5) | 0.642 |
| Positive | 11 (78.6) | 14 (87.5) | ||
| Missing | 2 | 4 | ||
| PgR status (primary) | Negative | 6 (42.9) | 5 (31.2) | 0.707 |
| Positive | 8 (57.1) | 11 (68.8) | ||
| Missing | 2 | 4 | ||
| HER2 status (primary) | Negative | 8 (61.5) | 10 (62.5) | 1 |
| Positive | 5 (38.5) | 6 (37.5) | ||
| Missing | 3 | 4 | ||
| Histological type (primary) | IDC (NST) | 12 (75.0) | 16 (88.9) | 0.410 |
| ILC | 2 (12.5) | 2 (11.1) | ||
| Other | 2 (12.5) | 0 (0.0) | ||
| Missing | 0 | 2 | ||
| Neoadjuvant chemotherapy | No | 7 (43.8) | 13 (76.5) | 0.080 |
| Yes | 9 (56.2) | 4 (23.5) | ||
| Missing | 0 | 3 | ||
| Menopausal status at metastatic diagnosis | Pre | 4 (28.6) | 6 (35.3) | 1 |
| Post | 10 (71.4) | 11 (64.7) | ||
| Missing | 2 | 3 | ||
| Age at metastatic diagnosis | ≤50 | 6 (37.5) | 9 (45.0) | 0.741 |
| >50 | 10 (62.5) | 11 (55.0) | ||
| ER status (met.) | Negative | 6 (37.5) | 7 (35.0) | 1 |
| Positive | 10 (62.5) | 13 (65.0) | ||
| PgR status (met.) | Negative | 7 (43.8) | 12 (60.0) | 0.503 |
| Positive | 9 (56.2) | 8 (40.0) | ||
| HER2 status (met.) | Negative | 11 (68.8) | 13 (65.0) | 1 |
| Positive | 5 (31.2) | 7 (35.0) | ||
| Nr hepatic met. lesions (preop.) | 1 | 8 (50.0) | 11 (55.0) | 1 |
| >1 | 8 (50.0) | 9 (45.0) | ||
| Extra hepatic met. | No | 12 (75.0) | 16 (80.0) | 1 |
| Yes | 4 (25.0) | 4 (20.0) | ||
| Interval primary/met. (years) | <1 year | 6 (37.5) | 3 (15.0) | 0.300 |
| 1–5 years | 5 (31.2) | 10 (50.0) | ||
| >5 years | 5 (31.2) | 7 (35.0) | ||
| ER status (P → LM) | Gain ER | 1 (7.1) | 1 (6.2) | 0.934 |
| Loss ER | 3 (21.4) | 5 (31.2) | ||
| Stable ER− | 2 (14.3) | 1 (6.2) | ||
| Stable ER+ | 8 (57.1) | 9 (56.2) | ||
| Missing | 2 | 4 | ||
| PgR status (P → LM) | Gain PgR | 3 (21.4) | 1 (6.2) | 0.622 |
| Loss PgR | 3 (21.4) | 6 (37.5) | ||
| Stable PgR− | 3 (21.4) | 4 (25.0) | ||
| Stable PgR+ | 5 (35.7) | 5 (31.2) | ||
| Missing | 2 | 4 | ||
| HER2 status (P → LM) | Gain HER2 | 1 (7.7) | 1 (6.2) | 1 |
| Loss HER2 | 2 (15.4) | 2 (12.5) | ||
| Stable HER2− | 7 (53.8) | 9 (56.2) | ||
| Stable HER2+ | 3 (23.1) | 4 (25.0) | ||
| Missing | 3 | 4 | ||
| Size largest lesion | <50 mm | 13 (81.2) | 18 (90.0) | 0.637 |
| ≥50 mm | 3 (18.8) | 2 (10.0) | ||
| Preoperative systemic treatment | No | 1 (6.2) | 1 (5.9) | 1 |
| Yes | 15 (93.8) | 16 (94.1) | ||
| Missing | 0 | 3 |
ER estrogen receptor, HGP histological growth pattern (D desmoplastic, R replacement), IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, LM liver metastasis, NST invasive carcinoma of no special type, P primary tumor, PgR progesterone receptor, TNM tumor–node–metastasis staging system.